MyFinsight
Home
Blog
About
Contact
Proceeds from follow-on
public offerings, net...
$391,550K
Proceeds from exercise of
common stock options
$1,669K
Net cash provided by
financing activities
$392,998K
Canceled cashflow
$221K
Net increase
(decrease) in cash and cash...
$1,210K
Canceled cashflow
$391,788K
Withholding taxes paid on net
exercise of stock options
$174K
Stock issuance costs
$47K
Proceeds from sales and
maturities of investments
$252,853K
Stock-based compensation
expense
$6,474K
Accounts payable
$2,522K
Unrealized losses (gains)
on short-term...
-$1,664K
Accrued expenses and
other current...
$1,607K
Depreciation and
amortization
$841K
Inventory
-$72K
Non-cash interest
expense (income)
-$46K
Non-cash lease expense
$13K
Net cash used in
investing activities
-$334,845K
Net cash used in
operating activities
-$56,943K
Canceled cashflow
$252,853K
Canceled cashflow
$13,239K
Purchases of investments
$587,394K
Net loss
-$60,202K
Purchases of property and
equipment
$304K
Prepaid expenses and
other current assets
$8,066K
Other assets
$998K
Accounts receivable, net
$587K
Other liabilities
-$329K
Back
Back
Cash Flow
CG Oncology, Inc. (CGON)
CG Oncology, Inc. (CGON)
source: myfinsight.com